Retrophin, Inc. (NASDAQ:RTRX) is set to announce third quarter earning results on Thursday 5th November 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, RTRX to report 3Q20 loss of $ 0.52 per share.
For the full year, analysts anticipate top line of $ 192.03 million, while looking forward to loss of $ 1.75 per share bottom line.
Previous Quarter Performance
Retrophin, Inc. revealed loss for the second quarter of $ 0.22 per share, from the revenue of $ 48.43 million. The quarterly revenues raised 8.32 percent compared with the same quarter last year. According to street consensus, RTRX was expected to report 2Q20 loss of $ 0.56 per share from revenue of $ 47.07 million. The bottom line results beat street analysts by $ 0.34 or 60.71 percent, at the same time, top line results outshined analysts by $ 1.36 million or 2.89 percent.
Stock Performance
Shares of Retrophin, Inc. traded up $ 0.50 or 2.41 percent on Wednesday, reaching $ 21.24 with volume of 457.20 thousand shares. Retrophin, Inc. has traded high as $ 22.49 and has cracked $ 20.74 on the downward trend
The closing price of $ 21.24, representing a 130.96 % increase from the 52 week low of $ 8.98 and a 7.78 % decrease over the 52 week high of $ 22.49.
The company has a market capital of $ 1.08 billion and is part of the Healthcare sector and Drug Manufacturers – Major industry.
Recent Analyst recommendations
- On 18th September 2020, initiated by Wedbush at Outperform rating, with $ 33.00 target price.
Conference Call
Retrophin, Inc. will be hosting a conference call at 4:30 PM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.retrophin.com
Retrophin, Inc., a biopharmaceutical company, focuses on the identification, development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria. The companys product candidates also consist of Fosmetpantotenate, a novel small molecule that is in Phase III clinical trial to treat pantothenate kinase-associated neurodegeneration; Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; CNSA-001, an orally bioavailable proprietary form of sepiapterin that is in phase II clinical trial for the treatment of phenylketonuria; and liquid ursodeoxycholic acid, a liquid formulation of ursodeoxycholic acid for the treatment of primary biliary cholangitis.
